FDA grants 510(k) clearance for Propeller digital therapy update

Propeller Health recently announced that the FDA has granted 510(k) clearance to market the next generation of its digital therapeutic platform for patients with asthma, COPD and other respiratory diseases.

The Propeller system is a “novel combination of sensors, mobile apps and analytics” used to encourage adherence to maintenance therapy and remotely monitor use of rescue medications for early intervention, according to a press release.

The new clearance will allow the Propeller system to help predict exacerbations in patients with asthma and COPD. The system will compare metered-dose inhaler use to a patient’s baseline and clinical guidelines, the release stated. The system will then alert a care teams as to patients who do not have the disease under control or are nearing an exacerbation.

The system can also be used for reminders, notifications and self-management education. An automated real-time coaching feature can include an inhaler technique that uses information captured during normal course of use, the release stated.

The new platform system is 30% smaller and supports Bluetooth Low Energy, according to the release.

“We remain focused on building ever better tools to provide people with coaching and guidance that is relevant, personalized and actionable, and make care teams more efficient through new opportunities to intervene,” David Van Sickle, chief executive officer of Propeller Health, said in the release.